Session
Pharmaceutical and Natural Sciences
Description
Excessive drug use causes Medication-overuse headache (MOH) which can be manifested with chronic daily headaches, occurring monthly 15 or more days when the medicament is used redundantly for more than three months. Recent studies concerning the epidemiology of drug-induced disorders suggest that an increased risk of nephrotoxicity appears in a group of patients who abuse NSAIDs. The aim is to confirm the early phase of nephrotoxicity in patients with (MOH), who were treated with NSAIDs in combination with other drugs (analgesics, triptans, and antidepressants) and compared patients treated only with Diclofenac, Piroxicam, Ketoprofen, Paracetamol, Ibuprofen, and Celecoxib. Besides conventional markers of renal functioning (serum/urine creatinine determined by Jaffe methods, enzymatic assay for urea serum). Imunoturbodimetric assay for determination of urinary albumin, microalbuminuria, and β2-microglobulin will be used. Significant glomerular and tubular damage has been reported, and patients on combination therapy with NSAIDs and other drugs (analgesics, triptans, and antidepressants) have seen more glomerular changes than patients treated with NSAID monotherapy.
Keywords:
Medication-overuse headache, Nephrotoxicity, Nonsteroidal antiinflammatory drugs
Proceedings Editor
Edmond Hajrizi
ISBN
978-9951-550-47-5
First Page
1
Last Page
10
Location
UBT Kampus, Lipjan
Start Date
30-10-2021 12:00 AM
End Date
30-10-2021 12:00 AM
DOI
10.33107/ubt-ic.2021.95
Recommended Citation
Havziu, Drita Yzeiri, "Evaluation a renal function of patients with Medication-overuse headache (MOH)" (2021). UBT International Conference. 23.
https://knowledgecenter.ubt-uni.net/conference/2021UBTIC/all-events/23
Included in
Evaluation a renal function of patients with Medication-overuse headache (MOH)
UBT Kampus, Lipjan
Excessive drug use causes Medication-overuse headache (MOH) which can be manifested with chronic daily headaches, occurring monthly 15 or more days when the medicament is used redundantly for more than three months. Recent studies concerning the epidemiology of drug-induced disorders suggest that an increased risk of nephrotoxicity appears in a group of patients who abuse NSAIDs. The aim is to confirm the early phase of nephrotoxicity in patients with (MOH), who were treated with NSAIDs in combination with other drugs (analgesics, triptans, and antidepressants) and compared patients treated only with Diclofenac, Piroxicam, Ketoprofen, Paracetamol, Ibuprofen, and Celecoxib. Besides conventional markers of renal functioning (serum/urine creatinine determined by Jaffe methods, enzymatic assay for urea serum). Imunoturbodimetric assay for determination of urinary albumin, microalbuminuria, and β2-microglobulin will be used. Significant glomerular and tubular damage has been reported, and patients on combination therapy with NSAIDs and other drugs (analgesics, triptans, and antidepressants) have seen more glomerular changes than patients treated with NSAID monotherapy.